Viatris, a global healthcare company with global centers in Pittsburgh, China and India, has completed its purchase of California-based Pacira BioSciences, a non-opioid pain management company.
Viatris purchased all of Pacira’s issued and outstanding shares of common stock for $36.50 per share in cash. Viatris’s wholly owned subsidiary Peach Purchaser Sub accepted for payment shares that were validly tendered and not validly withdrawn pursuant to the tender offer.
“Today marks an important milestone in the execution of our strategy to strengthen our U.S. innovative medicines business,” Scott A. Smith, Viatris CEO, said. “With Pacira now part of Viatris, we are bringing together complementary portfolios, capabilities and expertise to establish a leadership position in non-opioid pain management. We are excited to welcome our new Pacira colleagues as we create new opportunities to make a meaningful difference for patients and accelerate our path to sustained revenue and earnings growth.”
Pacira now is a wholly owned subsidiary of Viatris. It merged with Viatris without a Pacira’s stockholders vote. Shares that were not tendered in the tender offer were converted into the right to receive the offer price.
The transaction was announced on Oct. 8. Viatris expects the purchase will contribute between $90 million and $100 million in revenue for Nov. 17 through Dec. 31.